Abbott Laboratories 10-Q Summary
Business Context and Reporting Period
Abbott Laboratories reported results for the three months ended March 31, 2021. The company operates through four reportable segments: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices. The financial statements are unaudited and should be read with Abbott’s 2020 Form 10-K.
Key Financial Metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Net sales | $10.456 billion | $7.726 billion | +35.3% |
| Operating earnings | $2.109 billion | $758 million | +178.2% |
| Operating margin | 20.2% | 9.8% | +10.4 percentage points |
| Earnings from continuing operations | $1.793 billion | $544 million | +229.6% |
| Net earnings | $1.793 billion | $564 million | +218.0% |
| Diluted EPS | $1.00 | $0.31 | +222.6% |
| Gross margin | 53.0% | 50.3% | +2.7 percentage points |
| Net cash from operating activities | $2.637 billion | $715 million | +$1.922 billion |
- International sales were $6.618 billion, up 35.9%; U.S. sales were $3.838 billion, up 34.4%.
- Reported sales growth excluding foreign exchange was 32.9%. Excluding COVID-19 testing sales, total sales increased 7.6%, or 5.7% excluding both COVID-19 testing and foreign exchange.
- COVID-19 testing-related sales were approximately $2.2 billion, including approximately $1.8 billion from BinaxNOW, Panbio, and ID NOW rapid-testing platforms.
- Segment sales were $4.014 billion for Diagnostics, $3.320 billion for Medical Devices, $2.036 billion for Nutritional Products, and $1.070 billion for Established Pharmaceutical Products.
- Cash and cash equivalents increased to $8.054 billion from $6.838 billion at December 31, 2020. Working capital was $9.4 billion.
- Total debt was approximately $18.444 billion, consisting of $199 million of short-term borrowings, $756 million of current long-term debt, and $17.489 billion of long-term debt.
- Abbott had $5.0 billion of available credit lines expiring in 2025. Long-term debt ratings were A from Standard & Poor’s and A3 from Moody’s.
- Capital expenditures were $397 million. Dividends paid were $800 million, and share purchases were $275 million.
Material Changes Versus the Prior Comparable Period
- Diagnostics sales more than doubled, increasing 119.8%, primarily because of COVID-19 testing demand. Rapid Diagnostics sales increased 302.8% and Molecular Diagnostics sales increased 220.9% on a reported basis.
- Medical Devices sales increased 13.1%, led by Diabetes Care, Structural Heart, Electrophysiology, and Rhythm Management. FreeStyle Libre and Libre Sense sales increased 29.8% excluding foreign exchange to $829 million.
- Nutritional Products sales increased 6.9%, driven by adult nutrition, partly offset by lower pediatric nutrition sales.
- Established Pharmaceutical Products sales increased 2.5%, or 6.2% excluding foreign exchange.
- Gross margin improved because of higher volume, increased manufacturing utilization, and lower intangible amortization expense.
- Research and development expense increased 13.3% to $654 million, primarily due to higher spending on products in development. SG&A increased 9.2% to $2.783 billion, partly because of litigation charges and higher selling and marketing costs.
- Operating cash flow increased substantially, partly because pension contributions fell to $16 million from $320 million in the prior-year quarter. Cash taxes increased to approximately $270 million from $125 million.
- The first quarter of 2020 included $20 million of after-tax earnings from discontinued operations and related tax benefits; no such earnings were reported in 2021.
Outlook, Commentary, Risks, and Unusual Items
- The filing does not provide clear quantitative full-year earnings or revenue guidance.
- Management stated that the duration and impact of the COVID-19 pandemic remain unpredictable. Results benefited materially from COVID-19 testing demand, creating potential volatility if testing volumes or pricing decline.
- Medical device procedure volumes were still affected by elevated COVID-19 cases in certain countries. Heart Failure sales declined 6.2% excluding foreign exchange, and Vascular sales declined 2.0% excluding foreign exchange.
- Abbott faces competition, price controls, rebates, government regulation, reimbursement changes, healthcare policy uncertainty, foreign exchange exposure, and product and technological risks.
- Legal and environmental proceedings had an estimated possible loss range of approximately $215 million to $250 million, with an accrued balance of approximately $230 million at March 31, 2021. Management did not expect the ultimate disposition to materially affect financial position, cash flows, or results of operations.
- Remaining performance obligations were approximately $3.8 billion in Diagnostics and $400 million in Medical Devices. Abbott expects to recognize approximately 60% over the next 24 months and approximately 17% over the subsequent 12 months.
- Estimated annual intangible-asset amortization is approximately $2.0 billion in 2021 and 2022, and approximately $1.9 billion annually from 2023 through 2025.
- The board’s authorization to redeem up to $5 billion of long-term notes had $2.15 billion remaining at March 31, 2021. Abbott also had approximately $3.097 billion remaining under share-repurchase authorizations.
- Abbott declared a quarterly dividend of $0.45 per share, 25% higher than the $0.36 declared in the first quarter of 2020.
Important Facts for Investors to Verify
- Whether COVID-19 testing demand and related revenue remain durable or normalize materially in subsequent quarters.
- Underlying growth excluding COVID-19 testing and foreign exchange, particularly in Diagnostics and Medical Devices.
- Cash flow conversion after adjusting for the unusually favorable year-over-year change in pension contributions.
- Debt maturities, refinancing requirements, interest-rate exposure, and the planned use of debt-redemption capacity.
- Developments in litigation, environmental matters, tax examinations, and the approximately $230 million legal and environmental accrual.
- Recovery of procedure volumes in Heart Failure, Vascular, and other businesses affected by the pandemic.
- Future margins and earnings impact from intangible amortization, litigation costs, restructuring, and share-based compensation.